Table 2.

Novel agents for treatment of PTCL and their targeted pathways.

Target	Novel agents
Epigenomic mutations	HDAC inhibitors Hypomethylating agents EZH2 inhibitors
Signaling pathways/Kinase directed therapies	PI3Kinase inhibitors Janus kinase pathway inhibitors SYK pathway inhibitors Aurora kinase inhibitors ALK inhibitors
Cell surface receptors	CD 30 inhibitors CD 25 directed therapies
Tumor microenvironment	Immunomodulatory agents Check point inhibitors Anti-CD 47 agents
Non cell signaling pathways inhibition	Antiapoptotic therapies Farnesyl transferase inhibitors